ArticleACS omega2025
Rutin Protects Myocardial Ischemia-Reperfusion Injury via the NF-κB/NLRP3/Pyroptosis Pathway.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- The Role of Inflammation and Immunity in Cardiovascular Disease: Molecular Mechanisms and Therapeutic Targets.MedComm · 2026Review
- Exploring the role of the NLRP3 Inflammasome in polycystic ovary syndrome: therapeutic potential of herbal medicines.Journal of ovarian research · 2026Review
- Potential Relationship Between Ferroptosis and Pyroptosis in Myocardial Ischemia/Reperfusion Injury: Molecular Mechanisms and Therapeutic Targets.Reviews in cardiovascular medicine · 2026Review
- Identification of NF-κB pathway-related biomarkers in myocardial ischemia-reperfusion injury: based on transcriptomics analysis and RT-qPCR validation.Scientific reports · 2026Article
- Rutin as a Potential Therapeutic Agent for Multi-Organ Ischemia-Reperfusion Injury: From Multidimensional Mechanisms to Clinical Translation.Molecules (Basel, Switzerland) · 2026Review
- Delta opioid peptide (D-Ala2, D-Leu5)-enkephalin (DADLE) mitigates myocardial ischemia-reperfusion injury by inhibiting the TRAF6/NF-κB/NLRP3 pathway.Iranian journal of basic medical sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to determine the protective role and mechanism of rutin on myocardial ischemia-reperfusion (I/R) injury. First, a myocardial I/R injury model was established and subjected to ischemia and hypoxia to simulate the model of I/R injury in vivo. Triphenyltetrazolium chloride was used to determine the myocardial infarct area. Immunohistochemistry, the TUNEL assay, and hematoxylin and eosin staining were performed to determine NLRP3 expression, myocardial cell apoptosis, and cardiomyocyte morphology, respectively. Western blot analysis, the CCK-8 assay, and an ELISA were used to determine pyroptosis-associated protein expression, cell viability, and inflammatory factor expression, respectively. Rutin was shown to reduce the myocardial infarct area and myocardial cell apoptosis in vivo. Furthermore, rutin reduced the CK-MB, cTnT/I, and malondialdehyde levels after I/R injury. NLRP3 expression was downregulated after treatment with rutin compared to the sham group. NF-κB, NLRP3, cleaved caspase-1, and cleaved gasdermin D protein were also downregulated after rutin treatment. Rutin treatment enhanced cell viability after hypoxia-reperfusion conditions in
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.